Faricimab
Faricimab is a bispecific monoclonal antibody designed for intravitreal (intraocular) administration, developed for the treatment of retinal vascular diseases.
Faricimab is a bispecific monoclonal antibody designed for intravitreal (intraocular) administration, developed for the treatment of retinal vascular diseases. It is distinguished from conventional anti-VEGF therapies by its dual mechanism of action: faricimab simultaneously inhibits vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2), two critical mediators of retinal neovascularization, vascular permeability, and inflammation. VEGF-A is a well-established driver of pathological angiogenesis across multiple ocular conditions, and its role in diseases such as neovascular age-related macular degeneration (nAMD) has made it the target of a broad class of agents including aflibercept and brolucizumab. Angiopoietin-2 acts through the Tie-2 receptor pathway to destabilize existing vasculature and amplify the pro-angiogenic response, making its co-inhibition alongside VEGF-A a rationally motivated strategy for achieving more durable vascular stabilization.
The dual-target design of faricimab reflects a broader trend in bispecific antibody development across oncology and ophthalmology, where engaging two complementary pathways simultaneously can improve efficacy over single-target agents. In the retinal context, the combination of anti-vascular endothelial growth factor A (VEGFA) and anti-ANG-2 activity is hypothesized to normalize the diseased vasculature more completely than VEGF-A blockade alone, potentially extending treatment intervals and reducing injection burden for patients.
Where the papers sit
9 papers from the last 6 months study faricimab directly · updated from PubMed 6 Oct 2026
Study type 0 clinical trials · 5 observational · 1 human data · 3 unclassified
Themes 3 themes · 1 new direction
-
Neovascular AMD Treatment
Faricimab is moving into routine nAMD care for both treatment-naïve and highly refractory eyes. Real-world series emphasize rapid anatomical improvement and preservation or gain of best-corrected visual acuity after loading or switching. Comparisons with aflibercept frame faricimab as a second-line option when prior anti-VEGF therapy is inadequate. Subretinal fluid, ANGPT2 biology, and unusual degenerative findings remain part of the unresolved heterogeneity.
3 papers · 33.3%
-
Intravitreal Anti-VEGF Care
Intravitreal anti-VEGF care is being tracked through population-level use and post-injection safety signals. Japanese data describe changing injection patterns and regional variation across faricimab, aflibercept, and brolucizumab. Hypertensive anterior uveitis following faricimab adds a clinically important adverse-event signal. Together, the work supports continued surveillance of treatment utilization and ocular safety.
2 papers · 22.2%
-
Others — Retinal Outcomes and Treatment
Real-world retinal treatment is being judged by both anatomical response and functional vision. Faricimab is evaluated in refractory diabetic macular edema, treatment-naïve nAMD, and switches across retinal diseases, with best-corrected visual acuity and 12-month outcomes recurring. Hyperreflective foci and PS-OCT polarimetric entropy extend assessment beyond routine acuity and fluid measures. One paper instead addresses CAR T and bispecific antibodies in multiple myeloma, making the cluster non-coherent.
4 papers · 44.4%
Faricimab is implicated as a cause of hypertensive anterior uveitis rather than used only as retinal therapy
The three culture- and PCR-negative cases of hypertensive anterior uveitis following intravitreal faricimab 41990324Apr place faricimab in a role not represented by the other papers: a possible trigger of an inflammatory and pressure-related ocular complication. The assumption that faricimab is principally a treatment whose anatomical and functional effects are evaluated is therefore broadened to include a potential treatment-associated adverse ocular syndrome.
Papers
The 9 papers from the last 6 months that study faricimab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Neovascular AMD Treatment (3)
- Real-World Outcomes of Faricimab in Patients with Highly Refractory Neovascular Age-Related Macular Degeneration in Portugal: The REVEAL Study. Ophthalmology and therapy · 14 Jul 2026 PMID 42448987
- Real-world comparison of faricimab and aflibercept as second-line therapies for neovascular age-related macular degeneration. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2 Jul 2026 PMID 42390573
- Rapid Effects on Anatomical and Functional Outcomes following Upload with Faricimab in Treatment-Naïve nAMD: German Single-Center Study 45DRY. Ophthalmology and therapy · 25 Apr 2026 PMID 42033608
Intravitreal Anti-VEGF Care (2)
- Nationwide trends and regional variation in intravitreal injections and anti-VEGF agent use in Japan from 2017 to 2022: An analysis of the NDB Open Data. PloS one · 7 May 2026 PMID 42096458
- Hypertensive Anterior Uveitis Following Intravitreal Faricimab. Ocular immunology and inflammation · 16 Apr 2026 PMID 41990324
Others — Retinal Outcomes and Treatment (4)
- Use of faricimab for refractory diabetic macular edema in real-world clinical practice: When anatomical success meets functional limits. PloS one · 23 Sept 2026 PMID 42777000
- Faricimab for treatment-naïve nAMD: 1- and 2-year outcomes and PS-OCT polarimetric entropy. International ophthalmology · 20 Aug 2026 PMID 42622722
- Sequenced, Not Stirred: Positioning CAR T and Bispecific Antibody Therapy in Multiple Myeloma. Blood cancer discovery · 13 Aug 2026 PMID 42593166
- Switch to faricimab in various retinal diseases: real-world data. International ophthalmology · 2 May 2026 PMID 42068401
By study type
Observational studies and case reports (5)
- Use of faricimab for refractory diabetic macular edema in real-world clinical practice: When anatomical success meets functional limits. PloS one · 23 Sept 2026 PMID 42777000
- Faricimab for treatment-naïve nAMD: 1- and 2-year outcomes and PS-OCT polarimetric entropy. International ophthalmology · 20 Aug 2026 PMID 42622722
- Nationwide trends and regional variation in intravitreal injections and anti-VEGF agent use in Japan from 2017 to 2022: An analysis of the NDB Open Data. PloS one · 7 May 2026 PMID 42096458
- Switch to faricimab in various retinal diseases: real-world data. International ophthalmology · 2 May 2026 PMID 42068401
- Hypertensive Anterior Uveitis Following Intravitreal Faricimab. Ocular immunology and inflammation · 16 Apr 2026 PMID 41990324
Human data, design not indexed (1)
- Sequenced, Not Stirred: Positioning CAR T and Bispecific Antibody Therapy in Multiple Myeloma. Blood cancer discovery · 13 Aug 2026 PMID 42593166
Unclassified: not yet indexed with MeSH (3)
- Real-World Outcomes of Faricimab in Patients with Highly Refractory Neovascular Age-Related Macular Degeneration in Portugal: The REVEAL Study. Ophthalmology and therapy · 14 Jul 2026 PMID 42448987
- Real-world comparison of faricimab and aflibercept as second-line therapies for neovascular age-related macular degeneration. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2 Jul 2026 PMID 42390573
- Rapid Effects on Anatomical and Functional Outcomes following Upload with Faricimab in Treatment-Naïve nAMD: German Single-Center Study 45DRY. Ophthalmology and therapy · 25 Apr 2026 PMID 42033608
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-25 by GPT. Drafted by language models from published abstracts; not medical advice.